Stock VRP VERONA PHARMA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Verona Pharma plc London S.E.

Equities

VRP

GB00BYW2KH80

Biotechnology & Medical Research

Delayed London S.E.
Other stock markets
 16:35:15 29/10/2020 GMT 		5-day change 1st Jan Change
55 GBX +5.77% Intraday chart for Verona Pharma plc +4.76% -11.29%
06-27 Truist Securities Raises Price Target on Verona Pharma to $38 From $32, Maintains Buy Rating MT
06-27 Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 57.12 296.4 327.9 1,764 1,342 927.7 - -
Enterprise Value (EV) 2 26.48 163.3 216.7 1,573 1,166 743.8 781.3 747.6
P/E ratio -1.84 x -3.5 x -7 x -25.1 x -221 x -15.8 x -30.8 x -175 x
Yield - - - - - - - -
Capitalization / Revenue - - 10.9 x 4,633 x - 167 x 12.2 x 4.01 x
EV / Revenue - - 7.23 x 4,131 x - 134 x 10.3 x 3.23 x
EV / EBITDA -651,314 x -3,132,464 x - - - - - -
EV / FCF -781,950 x - - - - - - -
FCF Yield -0% - - - - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 13,173 57,899 66,021 81,634 85,951 81,082 - -
Reference price 3 5.750 7.000 6.720 26.13 19.88 14.46 14.46 14.46
Announcement Date 27/02/20 25/02/21 03/03/22 07/03/23 29/02/24 - - -
1USD in Million2GBP in Million3USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - 29.97 0.3807 - 5.549 76.02 231.4
EBITDA -40.65 -52.14 - - - - - -
EBIT 1 -41.08 -52.71 -54.92 -62.96 -53.4 -106.3 -77.42 43.97
Operating Margin - - -183.28% -16,539.32% - -1,915.49% -101.84% 19%
Earnings before Tax (EBT) 1 -39.21 -46.13 -41.64 -56.89 -42.59 -102.1 -74.15 42.07
Net income 1 -31.94 -46.23 -41.63 -57.1 -42.97 -103.4 -72.89 43.23
Net margin - - -138.92% -15,000.24% - -1,863.85% -95.88% 18.68%
EPS 2 -3.133 -2.000 -0.9600 -1.040 -0.0900 -0.9167 -0.4700 -0.0825
Free Cash Flow -33.86 - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 27/02/20 25/02/21 03/03/22 07/03/23 29/02/24 - - -
1GBP in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - 0.3807 - - - - - - 3.08 5.234 8.827 14.78
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -21.33 -20.04 -16.93 -13.08 -12.51 -17.58 -7.845 -13.45 -15.09 -21.73 -24.28 -28.28 -29.66 -29.07 -27.52
Operating Margin - - - - -3,285.81% - - - - - - -918.21% -566.65% -329.26% -186.17%
Earnings before Tax (EBT) 1 -17.61 -19.79 -14.6 -13.48 -8.663 -13.12 -6.689 -12.08 -11.21 -20.01 -23.45 -28.83 -29.89 -27.35 -26.24
Net income 1 -17.43 -19.86 -14.67 -13.53 -8.687 -13.26 -6.933 -12.11 -11.17 -20.61 -23.66 -29.1 -30.16 -27.54 -26.44
Net margin - - - - -2,281.88% - - - - - - -944.64% -576.25% -312.04% -178.82%
EPS 2 -0.4000 -0.4000 -0.3200 -0.0300 -0.1600 -0.2400 -0.0800 -0.1600 -0.0200 -0.0400 -0.1857 -0.2300 -0.2329 -0.1475 -0.1400
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 03/03/22 03/05/22 09/08/22 09/11/22 07/03/23 09/05/23 03/08/23 02/11/23 29/02/24 09/05/24 - - - - -
1GBP in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 30.6 133 111 191 177 184 146 180
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -33.9 - - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 0.04 - - - - - - -
Capex / Sales - - - - - - - -
Announcement Date 27/02/20 25/02/21 03/03/22 07/03/23 29/02/24 - - -
1GBP in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.46 USD
Average target price
35.71 USD
Spread / Average Target
+146.99%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
ARGENX SE Stock argenx SE
+18.95% 26.02B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VRNA Stock
  4. VRP Stock
  5. Financials Verona Pharma plc